NAMS
NewAmsterdam Pharma Company N.V.
Price Chart
Latest Quote
$31.40
+0.58 (+1.88%)
Current Price
| Previous Close | $30.82 |
| Open | $30.58 |
| Day High | $31.49 |
| Day Low | $30.31 |
| Volume | 995,189 |
Stock Information
| Shares Outstanding | 116.90M |
| Total Debt | $23K |
| Cash Equivalents | $636.11M |
| Revenue | $22.57M |
| Net Income | $-212.73M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.67B |
| EPS (TTM) | $-1.78 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.03B |
| Sales | $22.57M |
| Income | $-212.73M |
| Book/sh | $5.70 |
| Cash/sh | $5.44 |
| Employees | 100 |
Financial Ratios
| Quick Ratio | 9.56 |
| Current Ratio | 9.76 |
| Debt/Eq | 0.00 |
Returns & Margins
| ROA | -17.34% |
| ROE | -29.49% |
| Gross Margin | 100.00% |
| Operating Margin | -1921.71% |
Ownership
| Insider Ownership | 0.91% |
| Institutional Ownership | 106.20% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -24.68 |
| P/S | 162.68 |
| P/B | 5.51 |
Analyst Data
| Recommendation | none |
| Target Price | $48.98 |
Technical Indicators
| SMA20 | $31.79 |
| SMA50 | $32.80 |
| SMA200 | $33.34 |
| RSI | 48.04 |
| ATR | 1.6038 |
| Shares Float | 80.70M |
| Short Float | 8.14% |
| Short Ratio | 5.13 |
| Volatility | 0.08 |
| Rel Volume | 0.78 |
Performance History
| Week | +2.61% |
| Month | -12.14% |
| Quarter | +4.63% |
| 6 Months | -7.37% |
| YTD | -10.80% |
| Year | +74.83% |
| 3 Years | +158.01% |
| 5 Years | +220.08% |
| 10 Years | +195.89% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $31.40 | 999,800 |
| 2026-06-22 | $30.82 | 2,032,400 |
| 2026-06-18 | $29.83 | 1,250,200 |
| 2026-06-17 | $30.15 | 954,300 |
| 2026-06-16 | $30.19 | 1,156,600 |
| 2026-06-15 | $30.60 | 694,900 |
| 2026-06-12 | $30.40 | 673,500 |
| 2026-06-11 | $30.26 | 2,053,100 |
| 2026-06-10 | $29.33 | 861,000 |
| 2026-06-09 | $30.38 | 1,114,400 |
| 2026-06-08 | $30.95 | 512,900 |
| 2026-06-05 | $31.52 | 1,108,400 |
| 2026-06-04 | $32.67 | 1,457,500 |
| 2026-06-03 | $32.11 | 1,698,700 |
| 2026-06-02 | $31.71 | 1,999,000 |
| 2026-06-01 | $31.79 | 1,854,800 |
| 2026-05-29 | $33.68 | 2,460,100 |
| 2026-05-28 | $35.42 | 894,800 |
| 2026-05-27 | $36.56 | 938,800 |
| 2026-05-26 | $36.11 | 814,500 |
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
đ° Latest News
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness
Simply Wall St. âĸ 2026-06-11T10:11:13Z
Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026
Insider Monkey âĸ 2026-06-08T14:29:53Z
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
Motley Fool âĸ 2026-05-30T18:12:32Z
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
Motley Fool âĸ 2026-05-30T16:48:24Z
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Simply Wall St. âĸ 2026-05-11T16:37:20Z
Do NewAmsterdam Pharmaâs (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?
Simply Wall St. âĸ 2026-05-08T07:19:28Z
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
MarketBeat âĸ 2026-05-08T06:06:37Z
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-07T12:50:16Z
A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapibâs Phase 3 LDL C Results
Simply Wall St. âĸ 2026-04-09T16:16:20Z
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller
Insider Monkey âĸ 2026-04-08T20:29:10Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $22,503,000 | $45,563,000 | $14,090,000 | $102,694,000 |
| Operating Revenue | $22,503,000 | $45,563,000 | $14,090,000 | $102,694,000 |
| Expenses | ||||
| Total Expenses | $248,186,000 | $221,852,000 | $197,057,000 | $106,251,000 |
| Other Income Expense | $-5,728,000 | $-82,191,000 | $-5,226,000 | $-18,790,000 |
| Net Non Operating Interest Income Expense | $27,592,000 | $16,881,000 | $11,283,000 | $-287,000 |
| Operating Expense | $248,186,000 | $221,852,000 | $197,057,000 | $106,251,000 |
| General And Administrative Expense | $106,354,000 | $70,446,000 | $37,633,000 | $19,507,000 |
| Interest Expense | - | $0 | $0 | $287,000 |
| Interest Expense Non Operating | - | $0 | $0 | $287,000 |
| Total Other Finance Cost | - | - | $7,862,000 | $5,586,119 |
| Selling And Marketing Expense | - | - | $4,056,000 | $1,360,873 |
| Rent Expense Supplemental | - | - | - | $176,946 |
| Other Non Operating Income Expenses | - | - | - | $-8,002,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-203,819,000 | $-241,598,000 | $-176,937,000 | $-22,634,000 |
| Net Interest Income | $27,592,000 | $16,881,000 | $11,283,000 | $-287,000 |
| Interest Income | $27,592,000 | $16,881,000 | $11,283,000 | $0 |
| Normalized Income | $-198,091,000 | $-159,407,000 | $-173,059,308 | $-11,846,000 |
| Net Income From Continuing And Discontinued Operation | $-203,819,000 | $-241,598,000 | $-176,937,000 | $-22,634,000 |
| Total Operating Income As Reported | $-225,683,000 | $-176,289,000 | $-182,967,000 | $-3,557,000 |
| Net Income Common Stockholders | $-203,819,000 | $-241,598,000 | $-176,937,000 | $-22,634,000 |
| Net Income | $-203,819,000 | $-241,598,000 | $-176,937,000 | $-22,634,000 |
| Net Income Including Noncontrolling Interests | $-203,819,000 | $-241,598,000 | $-176,937,000 | $-22,634,000 |
| Net Income Continuous Operations | $-203,819,000 | $-241,598,000 | $-176,937,000 | $-22,634,000 |
| Pretax Income | $-203,819,000 | $-241,599,000 | $-176,910,000 | $-22,634,000 |
| Special Income Charges | $3,992,000 | $-37,010,000 | $-266,000 | $-707,000 |
| Interest Income Non Operating | $27,592,000 | $16,881,000 | $11,283,000 | $0 |
| Operating Income | $-225,683,000 | $-176,289,000 | $-182,967,000 | $-3,557,000 |
| Depreciation Amortization Depletion Income Statement | - | - | - | $77,213 |
| Depreciation And Amortization In Income Statement | - | - | - | $77,213 |
| Per Share | ||||
| Diluted EPS | $-1.78 | $-2.56 | $-2.15 | $-1.19 |
| Basic EPS | $-1.78 | $-2.56 | $-2.15 | $-1.19 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-1,348,308 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-219,735,000 | $-93,985,000 | $-177,692,000 | $-11,550,000 |
| Total Unusual Items | $-5,728,000 | $-82,191,000 | $-5,226,000 | $-10,788,000 |
| Total Unusual Items Excluding Goodwill | $-5,728,000 | $-82,191,000 | $-5,226,000 | $-10,788,000 |
| Reconciled Depreciation | $220,000 | $113,000 | $49,000 | $9,000 |
| EBITDA (Bullshit earnings) | $-225,463,000 | $-176,176,000 | $-182,918,000 | $-22,338,000 |
| EBIT | $-225,683,000 | $-176,289,000 | $-182,967,000 | $-22,347,000 |
| Diluted Average Shares | $114,399,326 | $94,358,067 | $82,161,956 | $18,966,235 |
| Basic Average Shares | $114,399,326 | $94,358,067 | $82,161,956 | $18,966,235 |
| Diluted NI Availto Com Stockholders | $-203,819,000 | $-241,598,000 | $-176,937,000 | $-22,634,000 |
| Tax Provision | $0 | $-1,000 | $27,000 | $0 |
| Restructuring And Mergern Acquisition | $-3,992,000 | $37,010,000 | $266,000 | $707,000 |
| Gain On Sale Of Security | $-9,720,000 | $-45,181,000 | $-4,960,000 | $-10,081,000 |
| Research And Development | $141,832,000 | $151,406,000 | $159,424,000 | $86,744,000 |
| Selling General And Administration | $106,354,000 | $70,446,000 | $37,633,000 | $19,507,000 |
| Other Gand A | $106,354,000 | $70,446,000 | $37,633,000 | $19,507,000 |
| Salaries And Wages | - | - | $17,136,000 | $5,380,219 |
| Insurance And Claims | - | - | - | $309,923 |
| Rent And Landing Fees | - | - | - | $176,946 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $683,024,000 | $756,966,000 | $288,223,000 | $429,858,000 |
| Total Assets | $769,284,000 | $864,620,000 | $347,097,000 | $478,497,000 |
| Total Non Current Assets | $93,584,000 | $1,207,000 | $306,000 | $518,000 |
| Investmentin Financial Assets | $92,609,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $407,000 | $534,000 | $170,000 | $208,000 |
| Current Assets | $675,700,000 | $863,413,000 | $346,791,000 | $477,979,000 |
| Restricted Cash | $1,321,000 | $0 | - | - |
| Prepaid Assets | $14,986,000 | $7,918,000 | $4,460,000 | $8,181,000 |
| Receivables | $23,152,000 | $21,305,000 | $1,881,000 | $2,070,000 |
| Other Receivables | $22,921,000 | $20,984,000 | $875,000 | - |
| Taxes Receivable | $231,000 | $321,000 | $1,006,000 | $2,070,000 |
| Cash Cash Equivalents And Short Term Investments | $636,241,000 | $834,190,000 | $340,450,000 | $467,728,000 |
| Cash And Cash Equivalents | $490,002,000 | $771,743,000 | $340,450,000 | $467,728,000 |
| Cash Equivalents | $270,608,000 | $37,917,000 | - | - |
| Cash Financial | $219,394,000 | $733,826,000 | $340,450,000 | $467,728,000 |
| Non Current Prepaid Assets | - | $0 | $35,000 | $156,000 |
| Non Current Note Receivables | - | - | - | $0 |
| Debt | ||||
| Total Debt | $202,000 | $448,000 | $60,000 | $126,000 |
| Long Term Debt And Capital Lease Obligation | $66,000 | $202,000 | $0 | $60,000 |
| Current Debt And Capital Lease Obligation | $136,000 | $246,000 | $60,000 | $66,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $85,853,000 | $107,120,000 | $58,704,000 | $48,431,000 |
| Total Non Current Liabilities Net Minority Interest | $66,000 | $202,000 | $8,807,000 | $12,374,000 |
| Current Liabilities | $85,787,000 | $106,918,000 | $49,897,000 | $36,057,000 |
| Other Current Liabilities | $57,272,000 | $82,312,000 | $12,574,000 | $4,147,000 |
| Current Deferred Liabilities | $3,987,000 | $6,008,000 | $8,942,000 | $13,874,000 |
| Payables And Accrued Expenses | $15,037,000 | $9,631,000 | $24,937,000 | $15,972,000 |
| Payables | $8,970,000 | $4,744,000 | $16,923,000 | $11,853,000 |
| Accounts Payable | $8,970,000 | $4,744,000 | $16,923,000 | $11,853,000 |
| Derivative Product Liabilities | - | $0 | $7,788,000 | $7,522,000 |
| Non Current Deferred Liabilities | - | $0 | $1,019,000 | $4,792,000 |
| Total Tax Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $683,431,000 | $757,500,000 | $288,393,000 | $430,066,000 |
| Total Equity Gross Minority Interest | $683,431,000 | $757,500,000 | $288,393,000 | $430,066,000 |
| Stockholders Equity | $683,431,000 | $757,500,000 | $288,393,000 | $430,066,000 |
| Gains Losses Not Affecting Retained Earnings | $4,793,000 | $4,467,000 | $4,422,000 | $4,422,000 |
| Other Equity Adjustments | $4,793,000 | $4,467,000 | - | $4,691,000 |
| Retained Earnings | $-762,390,000 | $-558,571,000 | $-316,973,000 | $-140,036,000 |
| Other | ||||
| Ordinary Shares Number | $114,399,326 | $108,064,340 | $82,469,768 | $81,559,780 |
| Share Issued | $114,399,326 | $108,064,340 | $82,469,768 | $81,559,780 |
| Tangible Book Value | $683,024,000 | $756,966,000 | $288,223,000 | $429,858,000 |
| Invested Capital | $683,431,000 | $757,500,000 | $288,393,000 | $430,066,000 |
| Working Capital | $589,913,000 | $756,495,000 | $296,894,000 | $441,922,000 |
| Capital Lease Obligations | $202,000 | $448,000 | $60,000 | $126,000 |
| Total Capitalization | $683,431,000 | $757,500,000 | $288,393,000 | $430,066,000 |
| Additional Paid In Capital | $1,426,750,000 | $1,298,160,000 | $590,771,000 | $555,625,000 |
| Capital Stock | $14,278,000 | $13,444,000 | $10,173,000 | $10,055,000 |
| Common Stock | $14,278,000 | $13,444,000 | $10,173,000 | $10,055,000 |
| Long Term Capital Lease Obligation | $66,000 | $202,000 | $0 | $60,000 |
| Current Deferred Revenue | $3,987,000 | $6,008,000 | $8,942,000 | $13,874,000 |
| Current Capital Lease Obligation | $136,000 | $246,000 | $60,000 | $66,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,355,000 | $8,721,000 | $3,384,000 | $1,998,000 |
| Current Accrued Expenses | $6,067,000 | $4,887,000 | $8,014,000 | $4,119,000 |
| Investments And Advances | $92,609,000 | $0 | - | - |
| Available For Sale Securities | $92,609,000 | - | - | - |
| Net PPE | $568,000 | $673,000 | $101,000 | $154,000 |
| Gross PPE | $568,000 | $673,000 | $101,000 | $154,000 |
| Other Properties | $568,000 | $673,000 | $101,000 | $154,000 |
| Other Short Term Investments | $146,239,000 | $62,447,000 | $0 | - |
| Foreign Currency Translation Adjustments | - | $4,467,000 | $4,422,000 | $4,422,000 |
| Non Current Deferred Revenue | - | $0 | $1,019,000 | $4,792,000 |
| Treasury Shares Number | - | - | $0 | - |
| Accumulated Depreciation | - | - | - | $-74,000 |
| Machinery Furniture Equipment | - | - | - | $46,000 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-148,029,000 | $-159,236,000 | $-141,242,000 | $10,444,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-147,783,000 | $-158,564,000 | $-141,218,000 | $10,665,000 |
| Cash Flow From Continuing Operating Activities | $-147,783,000 | $-158,564,000 | $-141,218,000 | $10,665,000 |
| Operating Gains Losses | $5,740,000 | $82,191,000 | $5,226,000 | $10,788,000 |
| Investing Activities | ||||
| Capital Expenditure | $-246,000 | $-672,000 | $-24,000 | $-221,000 |
| Investing Cash Flow | $-174,916,000 | $-62,848,000 | $-24,000 | $-221,000 |
| Cash Flow From Continuing Investing Activities | $-174,916,000 | $-62,848,000 | $-24,000 | $-221,000 |
| Net Other Investing Changes | - | - | - | $780,705 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $645,507,000 | $0 | $396,952,000 |
| Financing Cash Flow | $29,520,000 | $659,507,000 | $8,912,000 | $391,905,000 |
| Cash Flow From Continuing Financing Activities | $29,520,000 | $659,507,000 | $8,912,000 | $391,905,000 |
| Net Other Financing Charges | $-1,586,000 | $-1,529,000 | - | $-5,794,000 |
| Net Common Stock Issuance | $0 | $645,507,000 | $0 | $396,952,000 |
| Common Stock Issuance | $0 | $645,507,000 | $0 | $396,952,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $0 | $1,000 | $27,000 | $0 |
| End Cash Position | $491,323,000 | $771,743,000 | $340,450,000 | $467,728,000 |
| Beginning Cash Position | $771,743,000 | $340,450,000 | $467,728,000 | $60,131,000 |
| Effect Of Exchange Rate Changes | $12,759,000 | $-6,802,000 | $5,052,000 | $5,248,000 |
| Changes In Cash | $-293,179,000 | $438,095,000 | $-132,330,000 | $402,349,000 |
| Proceeds From Stock Option Exercised | $31,106,000 | $15,529,000 | $8,912,000 | $0 |
| Net Investment Purchase And Sale | $-174,670,000 | $-62,176,000 | $0 | $0 |
| Sale Of Investment | $122,063,000 | $0 | $0 | - |
| Purchase Of Investment | $-296,733,000 | $-62,176,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-246,000 | $-672,000 | $-24,000 | $-221,000 |
| Purchase Of PPE | $-246,000 | $-672,000 | $-24,000 | $-221,000 |
| Change In Working Capital | $-7,944,000 | $-32,674,000 | $5,866,000 | $10,373,000 |
| Change In Other Working Capital | $-2,021,000 | $-3,953,000 | $-8,705,000 | $18,428,000 |
| Change In Payables And Accrued Expense | $7,357,000 | $-11,262,000 | $10,540,000 | $-3,870,000 |
| Change In Accrued Expense | $2,448,000 | $1,686,000 | $5,470,000 | $-8,679,000 |
| Change In Payable | $4,909,000 | $-12,948,000 | $5,070,000 | $4,809,000 |
| Change In Account Payable | $4,909,000 | $-12,948,000 | $5,070,000 | $4,809,000 |
| Change In Prepaid Assets | $-13,280,000 | $-17,459,000 | $4,031,000 | $-4,185,000 |
| Stock Based Compensation | $59,425,000 | $33,619,000 | $24,572,000 | $4,117,000 |
| Amortization Of Securities | $-1,405,000 | $-227,000 | $0 | $0 |
| Depreciation Amortization Depletion | $220,000 | $113,000 | $49,000 | $9,000 |
| Depreciation And Amortization | $220,000 | $113,000 | $49,000 | $9,000 |
| Gain Loss On Investment Securities | $18,783,000 | $75,593,000 | $10,284,000 | $1,041,000 |
| Net Foreign Currency Exchange Gain Loss | $-13,055,000 | $6,598,000 | $-5,058,000 | $9,747,000 |
| Gain Loss On Sale Of PPE | $12,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-203,819,000 | $-241,598,000 | $-176,937,000 | $-22,634,000 |
| Issuance Of Debt | - | $0 | $0 | $747,000 |
| Interest Paid Supplemental Data | - | $0 | $0 | $277,000 |
| Net Issuance Payments Of Debt | - | $0 | $0 | $747,000 |
| Net Long Term Debt Issuance | - | $0 | $0 | $747,000 |
| Long Term Debt Issuance | - | $0 | $0 | $747,000 |
| Other Non Cash Items | - | $12,000 | $6,000 | $8,012,000 |
| Repayment Of Debt | - | - | - | $-69,706 |
| Long Term Debt Payments | - | - | - | $-69,706 |
| Interest Paid Cfo | - | - | - | $-280,968 |
Fetched: 2026-06-19